Dashboard
Manage Tickers

ABUS


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jefferies-maintains-buy-on-arbutus-biopharma-raises-price-target-to-7
Jefferies Maintains Buy on Arbutus Biophar...
09/05/2024 23:06:16

Jefferies analyst Dennis Ding maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and raises the price target from $5 to $7.

jmp-securities-maintains-market-outperform-on-arbutus-biopharma-raises-price-target-to-5
JMP Securities Maintains Market Outperform...
08/02/2024 17:55:14

JMP Securities analyst Roy Buchanan maintains Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and raises the price ...

trading-halt-halt-status-updated-at-75500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:55:...
08/01/2024 11:55:07

arbutus-will-cease-discovery-efforts-and-discontinue-its-im-prove-3-clinical-trial-to-focus-on-imdusiran-and-ab-101-the-company-will-reduce-its-workforce-by-40-incur-one-time-restructuring-charge-of-approximately-3m-4m-to-be-recorded-in-q3-of-2024
Arbutus Will Cease Discovery Efforts And D...
08/01/2024 11:35:24

With These Organizational Changes And Its Ongoing Cost Management Efforts, The Company Now Expects Its Current Cash, Cash Equiv...

arbutus-biopharma-q2-2024-gaap-eps-011-misses-010-estimate-sales-1726m-miss-1755m-estimate
Arbutus Biopharma Q2 2024 GAAP EPS $(0.11)...
08/01/2024 11:32:13

trading-halt-halted-at-72500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:25:00 a.m. ET - ...
08/01/2024 11:25:04

hc-wainwright--co-reiterates-buy-on-arbutus-biopharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Arbu...
06/07/2024 15:29:53

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

barinthus-biotherapeutics-presents-updated-data-from-two-clinical-trials-in-chronic-hepatitis-b-at-easl-congress-2024
Barinthus Biotherapeutics Presents Updated...
06/06/2024 15:16:01

In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed fo...

hc-wainwright--co-reiterates-buy-on-arbutus-biopharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Arbu...
06/06/2024 10:36:49

HC Wainwright & Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $5 price target.

chardan-capital-maintains-buy-on-arbutus-biopharma-maintains-4-price-target
Chardan Capital Maintains Buy on Arbutus B...
06/05/2024 20:20:24

Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.

arbutuss-imdusiran-combined-with-short-term-interferon-successfully-maintains-undetectable-hbsag-levels-essential-for-a-functional-cure-of-hbv
Arbutus's Imdusiran Combined With Short-Te...
06/05/2024 07:50:33

At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleo...

arbutus-biopharma-announces-presentation-of-imdusiran-data-at-easl-congress-2024
Arbutus Biopharma Announces Presentation O...
05/22/2024 06:29:12

Key Findings: HBsAg ≤ LLOQ (lower limit of quantification) with detectable anti-HBs was observed at end-of-treatment in 28% of ...

Core News & Articles
Genevant Sciences And Arbutus Biopharma Wi...
05/20/2024 16:52:06

https://storage.courtlistener.com/recap/gov.uscourts.njd.515917/gov.uscourts.njd.515917.35.0.pdf 

chardan-capital-reiterates-buy-on-arbutus-biopharma-maintains-4-price-target
Chardan Capital Reiterates Buy on Arbutus ...
05/03/2024 13:21:22

Chardan Capital analyst Keay Nakae reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $4 price target.

arbutus-biopharma-q1-eps-010-beats-011-estimate-sales-153m-miss-215m-estimate
Arbutus Biopharma Q1 EPS $(0.10) Beats $(0...
05/02/2024 11:31:35

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0...

arbutus-vs-moderna-patent-dispute-over-covid-19-vaccine-gets-response-from-judge
Arbutus Vs. Moderna Patent Dispute Over Co...
04/04/2024 18:32:00

Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

moderna-shares-slip-over-covid-vaccine-patent-dispute-but-chart-signals-potential-rebound-ahead
Moderna Shares Slip Over Covid Vaccine Pat...
04/04/2024 13:34:25

Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or avera...

jmp-securities-reiterates-market-outperform-on-arbutus-biopharma-maintains-4-price-target
JMP Securities Reiterates Market Outperfor...
04/04/2024 12:49:09

JMP Securities analyst Roy Buchanan reiterates Arbutus Biopharma (NASDAQ:ABUS) with a Market Outperform and maintains $4 pri...

Core News & Articles
Arbutus Biopharma Announces Claim Construc...
04/04/2024 12:42:17

The following summarizes the Court's Opinion:Composition of Total Lipid (‘069)The Court agreed with Plaintiffs' positio...

arbutus-stock-soars-20-as-it-heads-to-trial-with-moderna-in-covid-vaccine-patent-claim
Arbutus Stock Soars 20% As It Heads To Tri...
04/03/2024 19:37:15

Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against M...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION